Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Biologic Accepts Smaller Stake in Qianfeng Acquisition

publication date: Dec 19, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Biologic Products, Inc. announced a number of changes to the agreement under which it will acquire a 90% controlling interest in Chongqing Dalin Biologic Technologies Co., Ltd.  Dalin currently owns a 54% stake in Qianfeng Biological Products Co., Ltd. Like China Biologic, Qianfeng is a plasma-based biopharmaceutical company. While performing its due diligence, China Biologic found that Dalin owns only a 43.3% interest in Qianfeng instead of the 54% China Biologic originally bargained for. More details...

Stock Symbol: (OTCBB: CBPO)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...